Translation Control Therapeutics
See the light of Protein Translation
New approach
New technology
New drugs

AnimaBiotech

Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that specifically control mRNA translation

Read more

Translation Control Discovery Platform

Breakthrough Biology

Cloud Architecture

Proprietary Analysis

Labeled tRNA
library
Target
translation
Global
translation
Pathway
translation
Target
Identification
Hit selection &
de-risking
Big data
algorithms
Translation
image
analysis
tRNA
Bioinformatics
Translation Control Platform
We purified and fluorescently labeled all 48 types of human tRNA
Using FRET signals from signature tRNA pair(s) of the target protein, we visualize and monitor its translation
Using all 48 tRNA pairs together, we can monitor the cell’s complete protein translation activity
Using the signature pairs for its group of proteins, we can visualize and monitor the translation of a pathway
With multiple proprietary assays, our technology helps in identifying the molecular targets of translation modulating drugs
Multiple secondary assays use proprietary techniques to identify non-toxic compounds that specifically control the target’s translation
State of the art machine learning algorithms analyze billions of data points to identify translation modulating compounds
Proprietary image analysis algorithms run over millions of images to select images where the “translation light” has been affected
85% of known proteins have a “signature tRNA pair” that repeats with high frequency in their sequence but is relatively rare in the background human genome
Read more

A new strategy against hard and undruggable targets

Play Video

Specifically decrease or increase the production of target proteins

See the Light of Protein Translation

Translation Control Lab

Anima’s Translation Control Lab (TCL) is purpose-built for the discovery of translation modulators by integrating our proprietary technologies in biology, bioinformatics, big data image analysis and cloud software architecture

Anima Lab

PSM Assays
Screening
VPN

Cloud

Translation Data
Plate Processing
Plate Analysis
Image Analysis
PSM Image Creation
Plate Design
PSM Design
Big Data Visualisation
Bio Data Center
Big Data Analysis
• Experiment Design
• Analysis Assessment
• Bio Data Analysis
The Protein Synthesis Monitoring assay uses labeled tRNA pairs that generate FRET signals to monitor ribosome activity in selected cellular system.
PSM assay in a selected cellular system is used to screen a small molecule library of compounds towards the identification of compounds which change the PSM signal.
Unbiased scores are generated from more than 90 features extracted from images.
Images captured by Operetta® are automatically uploaded to the Cloud using proprietary plate processing software.
QA measures are executed to eliminate outliers wells and cells and to identify false positives.
State of the art image analysis algorithms extract unique PSM and additional cellular features as a feed for the big data analysis.
All images are captured by Operetta®, and the clean, calculated, PSM images is generated automatically.
FRET controls, assay controls are located at specific wells in all screens, enabling strict QA algorithms.
PSM design is based on proprietary mathematical algorithms analyzing the relevant RNA code.
Powerful visual and analytical tools enable us to view the results online from various mathematical and biological angles
All biological data and results are kept in a customized industry standard bio data center.
The analysis utilizes proprietary biological big data algorithms designed for translation control modulators discovery with high level of statistical significance.
Read more

Product Pipeline

Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors) and Huntington’s Disease (monitoring mutant Huntingtin translation pausing).

Program
Assay Development
Hit Generation
Hit to lead
Preclinical
Collagen I - Target1 Lung Fibrosis
Collagen I - Target2 Liver Fibrosis
Collagen I - Target3 Scleroderma
RSV Viral Translation Inhibitors
C-Myc Oncology / Longevity
Huntingtin Huntington's disease
Read more

Pharma Collaborations

Anima Biotech announces an exclusive collaboration with Lilly for the discovery and development of translation inhibitors of several protein targets

$30 million in upfront payments, $14 million in research funding, up to $1.05 billion in milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.

For partnering inquiries, please contact partnering@animabiotech.com.

17 Scientific Collaborations

Duke University
Oxford University
The Scripps Research Institute
Alma Mater Studiorum Università di Bologna
Consiglio Nazionale delle Ricerche
Gutenberg University
Haifa University
Hamburg University
Jefferson University
Massachusetts General Hospital
Penn University
Tel-Aviv University
Texas University
Unist
Torino University
Western University
See all collaborations

14 Publications

See all 14 publications

Coverage

Anima opens new target space in Translational Control May 24th, 2019

mRNA and Artificial Intelligence: An Interview with Anima Biotech’s Yochi Slonim May 23rd, 2019

Yochi Slonim Interview with Forbes Radio March 26th, 2019

Yochi Slonim Interview with Proactive Investors February 15th, 2019

Anima Biotech presentation at the 5th Annual LSX World Congress February 5th, 2019

Anima Biotech - Translation Control Therapeutics December 13th, 2018

Eli Lilly & Co. and Anima Biotech win US Deal of the Year at Lifestars Awards 2018 November 15th, 2018

Modulating the Production of Proteins to Treat Disease August 24th, 2018

Anima Biotech Lighting The Way In Protein Translation August 1st, 2018

This Israeli Biotech Targets Protein Translation to Fight Disease April 13th, 2018

See all media coverage

News & Events

  • European High Content Screening User Group Meeting

    When: May. 16th, 2019 - May. 17th, 2019
    Where: Barcelona, Spain

    Anima Biotech has been invited to present about the discovery of Protein Synthesis Modulators of "Undruggable" Targets using its Translation Control Therapeutics platform during the European High Content Screening User Group Meeting 2019.

    The European High Content Screening User Group Meeting provides a unique opportunity for users to appreciate the broad diversity of HCS applications; gain insights into new workflow solutions; share their experience, discuss challenges and learn about technology updates.

  • 11th Annual International ChinaBio Partnering Forum 2019

    When: May. 8th, 2019 - May. 9th, 2019
    Where: Shanghai, China

    Anima Biotech has been invited to present about its business, technology and partnering strategies during the 11thAnnual International ChinaBio Partnering Forum 2019.

    The ChinaBio Partnering Forum is the premier life science partnering event in China. The event will attract biotech and pharma leaders from around the world along with hundreds of China-based developers of novel technologies for two days of productive partnering.

    Download Press Release »

    Visit the conference website »

  • BioCentury 26th Annual Future Leaders in the Biotech Industry Conference

    When: Apr. 12th, 2019
    Where: New York, USA

    Anima Biotech has been invited to present and participate on a panel during the BioCentury 26th Annual Future Leaders in the Biotech Industry Conference.

    The Future Leaders Class of 2019 will showcase the next wave of investment opportunities in redefining disease, expanding the world of druggable targets, advancing next-generation modalities and applying AI to drug development.

    Download Press Release »

    Visit the conference website »

See all news & events